Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02543567 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
A Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
- Completed
- Registry status
- Phase 3
- Development phase
- 525
- Enrollment target
NCT02543567: Completed Phase 3 study, sponsored by Janssen Vaccines & Prevention B.V..
NCT02543567 is a Phase 3 study that has completed, run by Janssen Vaccines & Prevention B.V.. The registered enrollment target is 525 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02543567, a Phase 3 study, has completed, sponsored by Janssen Vaccines & Prevention B.V..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 525 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen with the recently released batches of Ad26.ZEBOV and MVA-BN-Filo in terms of humoral immune response against the Ebola virus (EBOV) GP (glycoprotein) as measured by enzyme-linked immunosorbent assay (ELISA) at 21 days post boost.
Primary Outcome
The humoral immune response will be assessed by enzyme-linked immunosorbent assay (ELISA) binding antibody
Interventions
- BIOLOGICAL Ad26.ZEBOV 5*10^10 viral particles (vp)
- BIOLOGICAL Ad26.ZEBOV 2*10^10 (vp)
- BIOLOGICAL Ad26.ZEBOV 0.8*10^10 (vp)
- BIOLOGICAL MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.]
- BIOLOGICAL MVA-BN-Filo 5*10^7 Inf. U.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 525 participants |
| Start Date | 2015-09-21 |
| Est. Completion | 2016-11-29 |
| Phase | Phase 3 |
What the finished NCT02543567 record still lists
NCT02543567 is an interventional study that assigns participants to a tested intervention. The registered 525 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (32% lower).
The record links to 0 conditions, and to 5 interventions - of which Ad26.ZEBOV 5*10^10 viral particles (vp) is the first listed.
NCT02543567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02543567 about?
NCT02543567 is a clinical study titled "A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants". The purpose of this study is to demonstrate the non-inferiority of a heterologous prime-boost regimen using Ad26.ZEBOV as prime and MVA-BN-Filo as boost administered at different doses at a 56-day interval versus the same regimen with the recently released batches of Ad26.ZEBOV and MVA-BN-Filo in te...
What is the current status of trial NCT02543567?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 525 participants. The study started on 2015-09-21. Estimated completion is 2016-11-29.
What interventions are being tested in trial NCT02543567?
The interventions under investigation include: Ad26.ZEBOV 5*10^10 viral particles (vp) (BIOLOGICAL), Ad26.ZEBOV 2*10^10 (vp) (BIOLOGICAL), Ad26.ZEBOV 0.8*10^10 (vp) (BIOLOGICAL), MVA-BN-Filo 1*10^8 Infectious Unit [Inf. U.] (BIOLOGICAL), MVA-BN-Filo 5*10^7 Inf. U. (BIOLOGICAL).
Who is sponsoring clinical trial NCT02543567?
This trial is sponsored by Janssen Vaccines & Prevention B.V., which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02543567's enrollment target sits among peer trials
525 715th of 2000 higher than 1,285 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04769492 · 525 participants · NA
#ChopViolence/#ChopHIV
- NCT05260047 · 525 participants · NA
Culturally Responsive Community Driven Substance Use Recovery for Black and Latinx Population
- NCT05620719 · 525 participants · NA
Multisite Advancement of Research on Chronic Posttraumatic Headache
- NCT06496646 · 525 participants · NA
Antidepressant Adherence for Depressed Adults in Primary Care
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI